Altana trial shows ciclesonide effective in asthma

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Altana Pharma AG said new efficacy data from a 12-week randomized study demonstrates that a "stepping-down" dose to 160 micrograms ciclesonide (Alvesco), a once-daily, novel, inhaled corticosteroid therapy for the treatment of asthma, is an equally effective maintenance treatment as 250 micrograms twice-daily fluticasone propionate (FP).

The median percentage of days where patients neither experienced asthma symptoms nor needed rescue medications was 97% for ciclesonide and 98% for FP.

Ciclesonide is approved in 38 countries for the treatment of persistent asthma in adults.

Altana, the pharmaceutical division of Altana AG, based in Konstanz, Germany, has filed a New Drug Application for ciclesonide with the Food and Drug Administration.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.